ReviewCurrent opinion in immunology2012
Vaccines for allergy.
Review in Current opinion in immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Structural Characterization of Food Allergens by Nuclear Magnetic Resonance Spectroscopy.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Liver-Targeting Nanoplatforms for the Induction of Immune Tolerance.Nanomaterials (Basel, Switzerland) · 2023Review
- In Silico Design of a New Epitope-Based Vaccine against Grass Group 1 Allergens.Advances in respiratory medicine · 2023Article
- Vaccination in the Era of Immunosuppression.Vaccines · 2023Review
- Review
- Prospective Use of Brown Spider Venom Toxins as Therapeutic and Biotechnological Inputs.Frontiers in molecular biosciences · 2021Review
- Incorporation of T-cell epitopes from tetanus and diphtheria toxoids into in-silico-designed hypoallergenic vaccine may enhance the protective immune response against allergens.Iranian journal of basic medical sciences · 2020Article
- A SARS-CoV-2 vaccine candidate:Informatics in medicine unlocked · 2020Article
- Analysis of predicted B and T-cell epitopes in Der p 23, allergen from Dermatophagoides pteronyssinus.Bioinformation · 2017Article
- A folded and immunogenic IgE-hyporeactive variant of the major allergen Phl p 1 produced in Escherichia coli.BMC biotechnology · 2015Article
- Mold allergens in respiratory allergy: from structure to therapy.Allergy, asthma & immunology research · 2015Review
- Food allergies: the basics.Gastroenterology · 2015Review
- Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.The Journal of allergy and clinical immunology · 2015Article
- Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2014Article
- Designing a multimer allergen for diagnosis and immunotherapy of dog allergic patients.PloS one · 2014Article
- Design of a ProDer f 1 vaccine delivered by the MHC class II pathway of antigen presentation and analysis of the effectiveness for specific immunotherapy.International journal of clinical and experimental pathology · 2014Article
- Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2013Review
- Engineering synthetic vaccines using cues from natural immunity.Nature materials · 2013Review
- Recombinant allergen immunotherapy: clinical evidence of efficacy--a review.Current allergy and asthma reports · 2013Review
- Safety of engineered allergen-specific immunotherapy vaccines.Current opinion in allergy and clinical immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Vaccines aim to establish or strengthen immune responses but are also effective for the treatment of allergy. The latter is surprising because allergy represents a hyper-immune response based on immunoglobulin E production against harmless environmental antigens, i.e., allergens. Nevertheless, vaccination with allergens, termed allergen-specific immunotherapy is the only disease-modifying therapy of allergy with long-lasting effects. New forms of allergy diagnosis and allergy vaccines based on recombinant allergen-derivatives, peptides and allergen genes have emerged through molecular allergen characterization. The molecular allergy vaccines allow sophisticated targeting of the immune system and may eliminate side effects which so far have limited the use of traditional allergen extract-based vaccines. Successful clinical trials performed with the new vaccines indicate that broad allergy vaccination is on the horizon and may help to control the allergy pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.